ArticleHepatology (Baltimore, Md.)2012
Regression of established hepatocellular carcinoma is induced by chemoimmunotherapy in an orthotopic murine model.
Article in Hepatology (Baltimore, Md.), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 47 citations in OpenAlex.
- ModulatingJournal for immunotherapy of cancer · 2026Article
- Advances in experimental animal models of hepatocellular carcinoma.Cancer medicine · 2023Review
- Nanoliposome C6-Ceramide in combination with anti-CTLA4 antibody improves anti-tumor immunity in hepatocellular cancer.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2022Article
- Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma.Journal for immunotherapy of cancer · 2020Article
- Mouse Models of Oncoimmunology in Hepatocellular Carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020Review
- Synergizing sunitinib and radiofrequency ablation to treat hepatocellular cancer by triggering the antitumor immune response.Journal for immunotherapy of cancer · 2020Article
- A Window of Opportunity: Targeting Cancer Endothelium to Enhance Immunotherapy.Frontiers in immunology · 2020Review
- Murine hepatoblast-derived liver tumors resembling human combined hepatocellular-cholangiocarcinoma with stem cell features.Cell & bioscience · 2020Article
- An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis.Journal of visualized experiments : JoVE · 2019Article
- Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa.Nature reviews. Clinical oncology · 2018Review
- Nanoliposome C6-Ceramide Increases the Anti-tumor Immune Response and Slows Growth of Liver Tumors in Mice.Gastroenterology · 2018Article
- Sunitinib and Sorafenib Modulating Antitumor Immunity in Hepatocellular Cancer.Journal of immunology research and therapy · 2018Article
- Harness the synergy between targeted therapy and immunotherapy: what have we learned and where are we headed?Oncotarget · 2017Review
- Therapeutic vaccine to cure large mouse hepatocellular carcinomas.Oncotarget · 2017Article
- Successful chemoimmunotherapy against hepatocellular cancer in a novel murine model.Journal of hepatology · 2017Article
- Development of inCVAX,Journal of clinical & cellular immunology · 2016Article
- A Selenium Containing Inhibitor for the Treatment of Hepatocellular Cancer.Pharmaceuticals (Basel, Switzerland) · 2016Article
- Immune-based Therapy Clinical Trials in Hepatocellular Carcinoma.Journal of clinical & cellular immunology · 2015Article
- Mouse models of liver cancer: Progress and recommendations.Oncotarget · 2015Review
- Development of a radiofrequency ablation platform in a clinically relevant murine model of hepatocellular cancer.Cancer biology & therapy · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 2 institutions in 1 country.
Funding
Abstract
unlabelledThe high rate of mortality and frequent incidence of recurrence associated with hepatocellular carcinoma (HCC) reveal the need for new therapeutic approaches. In this study we evaluated the efficacy of a novel chemoimmunotherapeutic strategy to control HCC and investigated the underlying mechanism that increased the antitumor immune response. We developed a novel orthotopic mouse model of HCC through seeding of tumorigenic hepatocytes from SV40 T antigen (Tag) transgenic MTD2 mice into the livers of syngeneic C57BL/6 mice. These MTD2-derived hepatocytes form Tag-expressing HCC tumors specifically within the liver. This approach provides a platform to test therapeutic strategies and antigen-specific immune-directed therapy in an immunocompetent murine model. Using this model we tested the efficacy of a combination of oral sunitinib, a small molecule multitargeted receptor tyrosine kinase (RTK) inhibitor, and adoptive transfer of tumor antigen-specific CD8(+) T cells to eliminate HCC. Sunitinib treatment alone promoted a transient reduction in tumor size. Sunitinib treatment combined with adoptive transfer of tumor antigen-specific CD8(+) T cells led to elimination of established tumors without recurrence. In vitro studies revealed that HCC growth was inhibited through suppression of STAT3 signaling. In addition, sunitinib treatment of tumor-bearing mice was associated with suppression of STAT3 and a block in T-cell tolerance.
conclusionThese findings indicate that sunitinib inhibits HCC tumor growth directly through the STAT3 pathway and prevents tumor antigen-specific CD8(+) T-cell tolerance, thus defining a synergistic chemoimmunotherapeutic approach for HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.